Mitogen-activated protein kinase 4

Description:

Description
  • Accession: P31152
  • Swissprot: MK04_HUMAN
  • Organism: Homo sapiens
  • Gene: MAPK4
  • Target class: Kinase

Drug Relations:

erlotinib
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER. Bioactivity details MOA
gefitinib
Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation. Bioactivity details MOA